Alcohol Use Disorder (AUD)NIBSSUDNCT05471154
Non-invasive Brain Stimulation of the Prefrontal Cortex in Substance Use Disorders
A study testing High Definition transcranial direct current stimulation (HD-tDCS) in people with Alcohol Use Disorder (AUD), run by Universitair Ziekenhuis Brussel at 1 site in Belgium.
Trial summary
Every year, alcohol causes 3 million deaths worldwide. Even though a lot of treatments already exist, many of them are characterized by a high percentage of drop-out or relapse. Transcranial direct current stimulation (tDCS), a NIBS, is receiving increased attention as a possible new addiction treatment. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Alcohol Use Disorder (AUD)
- What is being tested?
- High Definition transcranial direct current stimulation (HD-tDCS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- 1 siteBelgium
- Study dates
- 22 Sep 2022to 20 Sep 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- DSM-V criteria for alohol use disorder
- dutch speaking
- 18-65 years old
- abstinence in the past 10 days
Who cannot join
- diagnosis or family history of epilepsy
- a history of severe brain injury
- a cardiac pacemaker or electronic implants
- migraine
- a scalp skin condition
- pregnancy
Show all 10Show fewer
- concurrent treatment with benzodiazepines
- hairstyle incompatible with EEG-measurements
- a psychotic disorder or neurological disease
- severe cognitive impairment defined as a score lower than 10 on the Montreal Cognitive Assessment (MoCA).
Trial locations and contacts
1 site in 1 country.
About this study
Every year, alcohol causes 3 million deaths worldwide. Even though a lot of treatments already exist, many of them are characterized by a high percentage of drop-out or relapse. Transcranial direct current stimulation (tDCS), a NIBS, is receiving increased attention as a possible new addiction treatment. However, little consensus exists in the concrete parameters (e.g. montage, current, intensity). Moreover, a lot of tDCS research focuses on subjective outcomes, like the report of craving, which are more prone to different biases and fluctuations. In this study, we aim to investigate the effect of HD-tDCS, a more focal stimulation variant, on AUDs. Using this intervention, stimulation can be restricted to one hemisphere, controlling for possible inhibition effects of the cathode. A between-subject design will be carried out, including patients with an AUD. Participants will receive 5 sessions of either real or sham right anodal HD-tDCS over the dorsolateral prefrontal cortex (dlPFC). Craving will be accounted for at baseline and after every stimulation session. Moreover, we will measure the activity of the brain in rest and during two inhibition tasks (Go/NoGo and cue reactivity task). This objective measure will be carried out both before (baseline) and at two time points after the stimulation, to measure effects on both the short and longer term. One month after the intervention, abstinence will be checked through a follow-up phone call. Through this study, we aim to describe positive effects of right dlPFC stimulation on craving, abstinence, and EEG measures.
Read the detailed description
Population
This study will focus on patients with AUD, as these are the easiest to recruit. Participants in this study will be enrolled in a residential SUD treatment or a day hospital SUD treatment. As such, medical supervision can be guaranteed. In addition, sobriety is assessed objectively and routinely as part of TAU, enabling exclusion of patients under influence of alcohol. Cognitive impairment will be assessed using the MoCA and participants with a score below 10 (severe cognitive impairment) will be excluded.
Design
This study will use a between-subjects design. The experiment will be conducted double-blind to minimalize placebo effects and researcher bias. Group allocation will be conducted semi-randomly, with matching of participants' sex. The otherwise identical placebo protocol features sham stimulation (after a short ramp up, current drops again). The short ramp up is used to induce the same sensations as in the stimulation group (possible itching and tingling).
Measures
Self-report
Self-report measures will be collected prior to the intervention to discern endophenotypes predicting treatment response. The Behavioral Inhibition/Behavioral Activation System (BIS/BAS), Effortful Control Scales, Barrat Impulsiveness Scale and the Alcohol Use Disorders Identification Test (AUDIT) are collected. The Beck Depression Inventory (BDI) will be collected both before and after intervention.
Cognitive screening
The Montreal Cognitive Assessment (MoCA) will be used to exclude patients with severe cognitive impairment. Participants with a score of 10 or lower on the MoCA will be excluded from the study.
Medication regime
The medication regime of the participants will be registered, since medication may influence tDCS effects.
Resting state EEG
A resting state EEG is collected before the intervention as well as immediately after the first stimulation session and after the last stimulation session. These timepoints are used to collect data concerning the effect of tDCS on both short term and longer term.
ERPs and behavioral measures
Apart from resting state, event related potentials (ERP's) will be collected at the same time points, during different behavioral tasks: a cue reactivity task reflecting activation of the reward system and a Go-NoGo task reflecting executive functions, more concrete response inhibition.
- Cue-reactivity task: In this task, participants will be requested to indicate the occurrence of any infrequent stimulus by pressing the response button as fast as possible. Participants will be shown successions of pictures of a person drinking water (frequent), alcohol (infrequent) or soft drinks (equally infrequent). All stimuli will be presented in a random order. Three different alcohol-related pictures will be used, selected during the screening for alcohol preference.
- Go/NoGo task: In this task, participants have to press a button as fast as possible, whenever the Go stimulus (the letter M) is displayed. When another, infrequent stimulus is displayed (NoGo, the letter W), they have to refrain from pressing the button. The letters are superimposed on an alcohol-related picture or a non-alcohol related picture.
In both tasks, trials followed by incorrect responses will be eliminated from the data set. Reaction times and percentage of errors will be registered as behavioral measures.
Safety and blinding
After every session of HD-tDCS adverse effects will be assessed. Moreover, participants will systematically be asked whether they believe to have received real or placebo stimulation in the past session.
Subjective craving
A subjective craving measure will be carried out before the intervention and after every stimulation session.
Follow-up
1 month after the last stimulation session, verbally self-reported abstinence status will be registered. To do so, the Quick Drinking Screen (QDS) will be used.
Intervention
5 sessions of 2mA HD-tDCS (active or sham) will be used as intervention during 20 minutes.
- Conditions
- Alcohol Use Disorder (AUD)
- Being tested
- High Definition transcranial direct current stimulation (HD-tDCS)
- Keywords
- AUD, SUD, tDCS, NIBS, craving, abstinence, EEG
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High Definition transcranial direct current stimulation (HD-tDCS)Device
HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
| Study group | Role | What they receive |
|---|---|---|
| Active HD-tDCS | Experimental | Half of all subjects will receive active HD-tDCS (randomly assigned): anodal stimulation on the right dorsolateral prefrontal cortex. Stimulation will consist of 20 minutes 2mA anodal stimulation of the right dorsolateral prefrontal cortex. Receives: Device: High Definition transcranial direct current stimulation (HD-tDCS) |
| Sham HD-tDCS | Sham comparator | Half of all subjects will receive sham HD-tDCS (randomly assigned). A ramp-up of 1 minute will be used to induce the same feelings as during the active tDCS, but will then stop the stimulation. A short ramp up is repeated in the last minute of the protocol. Receives: Device: High Definition transcranial direct current stimulation (HD-tDCS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Abstinence
1 month after the last stimulation session, verbally self-reported abstinence status will be registered. To do so the Quick Drinking Screen (QDS) will be used during a phone call by the researcher.
Measured: 1 month after the intervention
Secondary outcomes (10)
ERP measures
We will measure the ERP during a cue-reactivity and a Go/NoGo task, pre-intervention, immediately after the first stimulation session and immediately after the last stimulation session.
Measured: Total estimated period of one week: pre-intervention (on day 1;T1), after a first stimulation session (day 1, 30 minutes after T1) and after the full intervention of 5 sessions (on day 5,4 days after T1)
Craving measures
subjective craving ratings on a Visual Analogue Scale (VAS), ranging from 0 to 10, 0 being no feeling of craving and 10 being very heavy feeling of craving
Measured: Total estimated period of one week: measure pre-intervention (day 1, T1) and after every stimulation session (T1 + 1 hour, T1 + 1 day, T1 + 2 days, T1 + 3 days and T1+ 4 days)
Effortful control scale (EC)
The effortful control scale aims to assess temperamental capacity for effortful control us-ing 19 items. The items need to be rated from 1 (not applicable) to 7 (very applicable) or X (never been in this situation)
Measured: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
resting state EEG in alpha band
Resting state EEG will be collected during 5 minutes. Afterwards, the power in the different frequency bands will be compared, focusing on prefrontal asymmetry in alpha power.
Measured: otal estimated period of one week: pre-intervention (on day 1;T1), after a first stimulation session (day 1, 30 minutes after T1) and after the full intervention of 5 sessions (on day 5,4 days after T1)
Behavioral inhibition system/behavioral approach system (BIS/BAS) Scale
The BIS/BAS questionnaire consists of 24 items. The questionnaire aims to measure the two motivational systems: the behavioral inhibition system and the behavioral approach system. Each item needs to be rated between 1 (true/applicable for me) to 4 (not true/applicable for me)
Measured: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
Barratt Impulsivity Scale (BIS)
the Barratt Impulsivity Scale (BIS-11) is a questionnaire that aims to assess impulsiveness as a personality construct. The Scale consists of 30 items, that need to be rated from "never/almost never" to "almost always"
Measured: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
Montreal Cognitive Assessment (MoCA)
the MoCA will be used to exclude patients with severe cognitive impairment. It is a short cognitive screening tool, that takes around 10 minutes to complete. The question-naire consists of one page with questions, for a total amount of 30 points. The different tasks focus on short term memory recall, visuospatial abilities, executive functions, at-tention, concentration and working memory, language and orientation to time and place. A score of 26 or higher is considered normal. For exclusion, we will use the cut off of 10 (severe cognitive impairment) in the Dutch version of the MoCA
Measured: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
screening alcohol preference
During the first meeting, participants will be shown pictures of various alcoholic drinks. Participants will be asked to rank these pictures based on how strong the craving they elicit. The highest ranked stimuli will be used in the behavioral / ERP tasks.
Measured: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
Alcohol Use Disorders Identification Test (AUDIT)
the AUDIT will be used to measure and objectify the severity of the participants' alcohol problem. The questionnaire consists of 10 questions and covers the domains of drinking behavior, alcohol consumption and alcohol-related problems. Questions need to be answered by indicating a value between 0 (Never/No/Few) and 4 (Daily/Yes/Almost daily)
Measured: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
Beck Depression Inventory (BDI)
the BDI will be used to measure depression and depressive symptoms. The questionnaire consists of 21 items aiming to measure symptoms like irritability, physical symptoms and helplessness.
Measured: The week before first day of intervention (T1) and after intervention (T2)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2022
- Study start22 Sep 2022
- Primary completion20 Sep 2024
- Study completion20 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol Use Disorder (AUD)Studies of the same condition, open and under way.
- More trials run by Universitair Ziekenhuis BrusselThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- In this study, High-Definition transcranial direct current stimulation is used as treatment/intervention (HD-tDCS). HD-tDCS will be applied with a current of 2 mA during 20 minutes. Participants are semi-randomly assigned to the two experimental groups (active stimulation vs. sham) by the coordinating researcher, taking into account the sex of the participant. The sham condition will use the same montage but stop stimulation after a short ramp-up of 1 minute).
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Natacha Deroost, PhD, Study chair, Vrije Universiteit BrusselKris Baetens, PhD, Study director, Vrije Universiteit BrusselGeert Dom, MD, Study chair, PC Multiversum BoechoutMarianne Destoop, MD, Study chair, PC Multiversum Boechout
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05471154
- Sponsor's protocol ID
- 22022NIBSSUD
- Acronym
- NIBSSUD
- Status last verified
- Dec 2024
- First submitted
- 6 Jul 2022
- Last updated
- 11 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-invasive Brain Stimulation of the Prefrontal Cortex in Substance Use Disorders
- ClinicalTrials.gov ID
- NCT05471154
- Acronym / sponsor ID
- NIBSSUD / 22022NIBSSUD
- Conditions
- Alcohol Use Disorder (AUD)
- Keywords
- AUD, SUD, tDCS, NIBS, craving, abstinence, EEG
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Universitair Ziekenhuis BrusselUniversity, hospital or other
- Study start
- 22 Sep 2022 (actual)
- Primary completion
- 20 Sep 2024 (actual)
- Study completion
- 20 Sep 2024 (actual)
- First posted
- 22 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Every year, alcohol causes 3 million deaths worldwide. Even though a lot of treatments already exist, many of them are characterized by a high percentage of drop-out or relapse. Transcranial direct current stimulation (tDCS), a NIBS, is receiving increased attention as a possible new addiction treatment. However, little consensus exists in the concrete parameters (e.g. montage, current, intensity). Moreover, a lot of tDCS research focuses on subjective outcomes, like the report of craving, which are more prone to different biases and fluctuations. In this study, we aim to investigate the effect of HD-tDCS, a more focal stimulation variant, on AUDs. Using this intervention, stimulation can be restricted to one hemisphere, controlling for possible inhibition effects of the cathode. A between-subject design will be carried out, including patients with an AUD. Participants will receive 5 sessions of either real or sham right anodal HD-tDCS over the dorsolateral prefrontal cortex (dlPFC). Craving will be accounted for at baseline and after every stimulation session. Moreover, we will measure the activity of the brain in rest and during two inhibition tasks (Go/NoGo and cue reactivity task). This objective measure will be carried out both before (baseline) and at two time points after the stimulation, to measure effects on both the short and longer term. One month after the intervention, abstinence will be checked through a follow-up phone call. Through this study, we aim to describe positive effects of right dlPFC stimulation on craving, abstinence, and EEG measures.
Detailed description
Population
This study will focus on patients with AUD, as these are the easiest to recruit. Participants in this study will be enrolled in a residential SUD treatment or a day hospital SUD treatment. As such, medical supervision can be guaranteed. In addition, sobriety is assessed objectively and routinely as part of TAU, enabling exclusion of patients under influence of alcohol. Cognitive impairment will be assessed using the MoCA and participants with a score below 10 (severe cognitive impairment) will be excluded.
Design
This study will use a between-subjects design. The experiment will be conducted double-blind to minimalize placebo effects and researcher bias. Group allocation will be conducted semi-randomly, with matching of participants' sex. The otherwise identical placebo protocol features sham stimulation (after a short ramp up, current drops again). The short ramp up is used to induce the same sensations as in the stimulation group (possible itching and tingling).
Measures
Self-report
Self-report measures will be collected prior to the intervention to discern endophenotypes predicting treatment response. The Behavioral Inhibition/Behavioral Activation System (BIS/BAS), Effortful Control Scales, Barrat Impulsiveness Scale and the Alcohol Use Disorders Identification Test (AUDIT) are collected. The Beck Depression Inventory (BDI) will be collected both before and after intervention.
Cognitive screening
The Montreal Cognitive Assessment (MoCA) will be used to exclude patients with severe cognitive impairment. Participants with a score of 10 or lower on the MoCA will be excluded from the study.
Medication regime
The medication regime of the participants will be registered, since medication may influence tDCS effects.
Resting state EEG
A resting state EEG is collected before the intervention as well as immediately after the first stimulation session and after the last stimulation session. These timepoints are used to collect data concerning the effect of tDCS on both short term and longer term.
ERPs and behavioral measures
Apart from resting state, event related potentials (ERP's) will be collected at the same time points, during different behavioral tasks: a cue reactivity task reflecting activation of the reward system and a Go-NoGo task reflecting executive functions, more concrete response inhibition.
- Cue-reactivity task: In this task, participants will be requested to indicate the occurrence of any infrequent stimulus by pressing the response button as fast as possible. Participants will be shown successions of pictures of a person drinking water (frequent), alcohol (infrequent) or soft drinks (equally infrequent). All stimuli will be presented in a random order. Three different alcohol-related pictures will be used, selected during the screening for alcohol preference.
- Go/NoGo task: In this task, participants have to press a button as fast as possible, whenever the Go stimulus (the letter M) is displayed. When another, infrequent stimulus is displayed (NoGo, the letter W), they have to refrain from pressing the button. The letters are superimposed on an alcohol-related picture or a non-alcohol related picture.
In both tasks, trials followed by incorrect responses will be eliminated from the data set. Reaction times and percentage of errors will be registered as behavioral measures.
Safety and blinding
After every session of HD-tDCS adverse effects will be assessed. Moreover, participants will systematically be asked whether they believe to have received real or placebo stimulation in the past session.
Subjective craving
A subjective craving measure will be carried out before the intervention and after every stimulation session.
Follow-up
1 month after the last stimulation session, verbally self-reported abstinence status will be registered. To do so, the Quick Drinking Screen (QDS) will be used.
Intervention
5 sessions of 2mA HD-tDCS (active or sham) will be used as intervention during 20 minutes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- In this study, High-Definition transcranial direct current stimulation is used as treatment/intervention (HD-tDCS). HD-tDCS will be applied with a current of 2 mA during 20 minutes. Participants are semi-randomly assigned to the two experimental groups (active stimulation vs. sham) by the coordinating researcher, taking into account the sex of the participant. The sham condition will use the same montage but stop stimulation after a short ramp-up of 1 minute).
| Arm | Type | Receives |
|---|---|---|
| Active HD-tDCS | Experimental | Device: High Definition transcranial direct current stimulation (HD-tDCS)Half of all subjects will receive active HD-tDCS (randomly assigned): anodal stimulation on the right dorsolateral prefrontal cortex. Stimulation will consist of 20 minutes 2mA anodal stimulation of the right dorsolateral prefrontal cortex. |
| Sham HD-tDCS | Sham comparator | Device: High Definition transcranial direct current stimulation (HD-tDCS)Half of all subjects will receive sham HD-tDCS (randomly assigned). A ramp-up of 1 minute will be used to induce the same feelings as during the active tDCS, but will then stop the stimulation. A short ramp up is repeated in the last minute of the protocol. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- DSM-V criteria for alohol use disorder
- dutch speaking
- 18-65 years old
- abstinence in the past 10 days
Key exclusion criteria (10 listed)
- diagnosis or family history of epilepsy
- a history of severe brain injury
- a cardiac pacemaker or electronic implants
- migraine
- a scalp skin condition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High Definition transcranial direct current stimulation (HD-tDCS)HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America. | Device | Active HD-tDCS, Sham HD-tDCS |
Primary outcome
Abstinence
Time frame: 1 month after the intervention
1 month after the last stimulation session, verbally self-reported abstinence status will be registered. To do so the Quick Drinking Screen (QDS) will be used during a phone call by the researcher.
10 secondary outcomes
ERP measures
Time frame: Total estimated period of one week: pre-intervention (on day 1;T1), after a first stimulation session (day 1, 30 minutes after T1) and after the full intervention of 5 sessions (on day 5,4 days after T1)
Craving measures
Time frame: Total estimated period of one week: measure pre-intervention (day 1, T1) and after every stimulation session (T1 + 1 hour, T1 + 1 day, T1 + 2 days, T1 + 3 days and T1+ 4 days)
Effortful control scale (EC)
Time frame: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
resting state EEG in alpha band
Time frame: otal estimated period of one week: pre-intervention (on day 1;T1), after a first stimulation session (day 1, 30 minutes after T1) and after the full intervention of 5 sessions (on day 5,4 days after T1)
Behavioral inhibition system/behavioral approach system (BIS/BAS) Scale
Time frame: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
Barratt Impulsivity Scale (BIS)
Time frame: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
Montreal Cognitive Assessment (MoCA)
Time frame: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
screening alcohol preference
Time frame: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
Alcohol Use Disorders Identification Test (AUDIT)
Time frame: The week before first day of intervention (T1), during a block of questionnaires (estimated at 1 hour in time spending)
Beck Depression Inventory (BDI)
Time frame: The week before first day of intervention (T1) and after intervention (T2)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Alcohol Use Disorder (AUD)
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
Not yet recruiting
Examining the Relationship Between Ongoing Alcohol Use, Suicidal Thoughts and Behaviors and Related Constructs, and Behavioral Economic Decision-Making.
Alcohol Use Disorder (AUD), Suicidal Ideation
Not yet recruitingObservational study
Disease Intervention Specialist (DIS) for SUD
Substance Use Disorder (SUD), Opioid Use Disorder
Not yet recruiting
Deaf CBT-TS to Reduce Suicide Risk
Depression - Major Depressive Disorder, Anxiety
Not yet recruiting
eTSF for Latinx Young Adults With Alcohol Use Disorder
Alcohol Use Disorder (AUD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Natacha Deroost, PhD study chair
Vrije Universiteit Brussel
Kris Baetens, PhD study director
Vrije Universiteit Brussel
Geert Dom, MD study chair
PC Multiversum Boechout
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High Definition transcranial direct current stimulation (HD-tDCS) in people with Alcohol Use Disorder (AUD), run by Universitair Ziekenhuis Brussel at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Abstinence (time frame: 1 month after the intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2025.